Edition:
United States

Idera Pharmaceuticals Inc (IDRA.OQ)

IDRA.OQ on NASDAQ Stock Exchange Capital Market

2.00USD
18 May 2018
Change (% chg)

$0.05 (+2.56%)
Prev Close
$1.95
Open
$1.98
Day's High
$2.03
Day's Low
$1.96
Volume
225,011
Avg. Vol
303,280
52-wk High
$2.87
52-wk Low
$1.32

Select another date:

Wed, May 9 2018

BRIEF-Idera Pharmaceuticals Reports Q1 Loss Per Share $0.10

* IDERA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Idera Pharmaceuticals Enters Into A Clinical Development Support Agreement With Pillar Partners Foundation

* IDERA PHARMACEUTICALS ENTERS INTO A CLINICAL DEVELOPMENT SUPPORT AGREEMENT WITH PILLAR PARTNERS FOUNDATION TO EXPAND THE CLINICAL RESEARCH ON IMO-2125 BEYOND PD-1 REFRACTORY MELANOMA

BRIEF-Biocryst Pharmaceuticals And Idera Pharmaceuticals Reschedule Meetings To Vote On Proposed Merger

April 10 Idera Pharmaceuticals Inc - New Clinical Data On Idera's Imo :

BRIEF-Idera Pharma Files Definitive Proxy Statement Over With Pending Merger With Biocryst

* IDERA PHARMACEUTICALS FILES DEFINITIVE PROXY STATEMENT IN CONNECTION WITH PENDING MERGER WITH BIOCRYST PHARMACEUTICALS

BRIEF-RA Capital Management Opposes BioCryst Pharmaceuticals' Proposed Merger With Idera Pharmaceuticals

* RA CAPITAL MANAGEMENT OPPOSES BIOCRYST PHARMACEUTICALS' PROPOSED MERGER WITH IDERA PHARMACEUTICALS

BRIEF-Biocryst Pharmaceuticals Files Definitive Proxy Statement Related To Pending Merger With Idera Pharmaceuticals

* BIOCRYST PHARMACEUTICALS FILES DEFINITIVE PROXY STATEMENT IN CONNECTION WITH PENDING MERGER WITH IDERA PHARMACEUTICALS

BRIEF-Idera Pharmaceuticals Reports Q4 Loss Per Share $0.08

* IDERA PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Idera Pharma Announces Launch Of Phase 3 Trial Evaluating IMO-2125 In Combination With Ipilimumab

* IDERA PHARMACEUTICALS ANNOUNCES LAUNCH OF GLOBAL PHASE 3 TRIAL EVALUATING IMO-2125 IN COMBINATION WITH IPILIMUMAB FOR THE TREATMENT OF ANTI-PD-1 REFRACTORY MELANOMA (ILLUMINATE 301) Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Great Point Partners Opposes Biocryst Pharma Proposed Merger With Idera Pharma

* GREAT POINT PARTNERS LLC OPPOSES THE BIOCRYST PHARMACEUTICAL PROPOSED MERGER WITH IDERA PHARMACEUTICALS, INC.

BRIEF-Biocryst Pharma And Idera Pharma Sign Merger Agreement To Form New Company

* BIOCRYST PHARMACEUTICALS AND IDERA PHARMACEUTICALS ANNOUNCE MERGER TO COMBINE CAPABILITIES TO SERVE MORE PATIENTS WITH RARE DISEASES

Select another date: